Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2008
11/06/2008US20080274986 Drug delivery system for accurate fluid dosing onto ingestible medium followed by vehicle evaporation; simplifies manufacturing and distribution; strength variability
11/06/2008US20080274985 Pharmaceutical composition useful for the treatment of peptic ulcer diseases
11/06/2008US20080274984 Method, composition and kit for antigenic binding of norwalk-like viruses
11/06/2008US20080274983 Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases
11/06/2008US20080274967 Variants of Pigment Epithelium Derived Factor and Uses Thereof
11/06/2008US20080274962 Voltage Dependent Anion Channel (Vdac1) Compositions and Methods of Use Thereof for Regulating Apoptosis
11/06/2008US20080274947 Antilipemic agents; metabolic disorders; insulin resistance; antidiabetic agents
11/06/2008US20080274946 Method and composition for restoration of age related tissue loss in the face or selected areas of the body
11/06/2008US20080274893 Spirocyclic 3-Phenyl-3substituted-4-Ketolactams and-lactones
11/06/2008US20080274882 Synergistic mixture of imidacloprid, thiacloprid, acetamiprid, nitenpyram, thiamethoxam with strobilurin fungicide such as pyraclostrobin
11/06/2008US20080274213 Inhibits reduction in blood testosterone level; extracts of genus Codonopsis; no side effects
11/06/2008US20080274209 Methods of treating inflammation
11/06/2008US20080274203 Having high amounts of phospholipids, astaxanthin esters and/or omega-3 contents; antiinflammation, antioxidant effects, improving insulin resistance and blood lipid profile
11/06/2008US20080274202 Compositions and Method for Brain Specific Targeted Delivery of Therapeutic Agents
11/06/2008US20080274200 Dose titratable liquid dosage forms of acid labile drugs
11/06/2008US20080274197 Lyophilized formulation
11/06/2008US20080274196 Bioequivalent to tablet dosage form; combination of compacted and plain powder; controlled particle size; bioavailability without enhancing substances
11/06/2008US20080274195 Compositions and Methods for Making and Using Nanoemulsions
11/06/2008US20080274193 Retinoic Acid-Containing Antidiabetic Agent
11/06/2008US20080274192 Pharmaceutical Compositions Comprising an Amorphous Form of a Vegf-R-Inhibitor
11/06/2008US20080274189 Organic Compounds Comprising a Glycopyrr Onium Salt
11/06/2008US20080274184 Extracellular matrix (ECM) combined with therapeutic agents; promoting tissue wound healing; reducing side effects
11/06/2008US20080274183 Melt extrudable, polymeric fiber suitable for controlled, sustained internal administration; blend of cellulose alkyl ester and secondary biocompatible polymer
11/06/2008US20080274182 Rapid, low energy drying without loss of protective and/or swallowing properties; enzymatic molecular weight reduction; minimizing solvent requirements
11/06/2008US20080274177 Monolithic coating comprising aqueous dispersion of neutral acrylic ester copolymer without any functional groups and polyglycol; short curing times; shelf life
11/06/2008US20080274176 Pharmaceutical Lipid Compositions
11/06/2008US20080274175 Compositions Comprising Edible Oils and Vitamins and/or Minerals and Methods for Making the Compositions
11/06/2008US20080274173 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
11/06/2008US20080274171 Renin Inhibitors Nitroderivatives
11/06/2008US20080274169 Flexible, penetrating liposomal carrier system; bilayer of phospholipids, a hydrophobic photosensitizer, skin penetration enhancers; penetrating through an intact stratum corneum or wound surface without removal of photosensitizer from bilayer without agglomeration of bilayers
11/06/2008US20080274168 Transdermal delivery device disposal system
11/06/2008US20080274167 Impermeable backing layer, an active substance layer of sufentanyl and a polymer mixture with microreservoirs dispersed, an active substance dissolved in the microreservoirs
11/06/2008US20080274164 Atrium Patch
11/06/2008US20080274159 Drug formulations for coating medical devices
11/06/2008US20080274158 biodegradable hydrogel FGF-beta mimetic; PEG-dihydrazide crosslinking agent for a desamino-tyrosyl-tyrosine dipeptide or polypeptides thereof; implantable resorbable medical device; wound healing; the water soluble polymer can also be polysaccharide, polyvinyl alcohol or poly(N-methyl pyrrolidone)
11/06/2008US20080274156 Surgical implant, prosthesis or bioscaffold of isolated heparin sulphate from bone, bone cell, bone precursor cell or stem cell
11/06/2008US20080274155 Chimeric Cannulae Proteins, Nucleic Acids Encoding Them And Methods For Making And Using Them
11/06/2008US20080274149 Encapsulation and Controlled Release of Biologically Active Ingredients with Enzymatically Degradable Microparticulate, Hyperbranched Polymers
11/06/2008US20080274141 Animal cells and processes for the replication of influenza viruses
11/06/2008US20080274127 Using probiotic nutrient mix comprising synthetic peptides, free amino acids and/or protein hydrolysates as therapeutic in treatment of gastrointestinal distress and to enhance immune system response
11/06/2008US20080274122 Plks as Modifiers of the Beta Catenin Pathway and Methods of Use
11/06/2008US20080274121 Inhibition of Angiogenesis by Mithramycin
11/06/2008US20080274120 Antiproliferative agents; kits; antibodies against VEGF, an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan
11/06/2008US20080274119 Use of Opioid Antagonists to Attenuate Endothelial Cell Proliferation and Migration
11/06/2008US20080274107 Tyrosine kinase inhibitors
11/06/2008US20080274104 Targeting a Secreted Pro-Apoptotic Factor for Cancer Therapeutics
11/06/2008US20080274103 Adenylyl Cyclase Antibodies, Compositions and Uses Thereof
11/06/2008US20080274099 Oncofoetal domain specific immunoglobulin for use in diagnosis, prevention and treatment of cell proliferative disorders
11/06/2008US20080274097 Using ultrasonic vibration at treatment sites to enhance efficacy of therapeutic treatment
11/06/2008US20080274094 Molecular Complex Comprising Arbutine, Ascorbic Acid, Oleuropeina or Its Derivatives Thereof and Related Uses In Medical Field
11/06/2008US20080274080 Aza-peptide macrocyclic hepatitis c serine protease inhibitors
11/06/2008US20080274079 Using mifepristone, cacl2, and/or metyrapone as therapeutic antagonist in treatment of skin disorders; wound healing agents; antiscarring agents
11/06/2008US20080274077 Using Nogo receptor suppressant as therapeutic in treatment of nervous system and neurodegenerative disorders; axonal regeneration
11/06/2008US20080274075 PEG-derived cyanoacetamides and PEG-derived phosphonium salts undergo smooth reaction with protein-derived aldehydes or ketones in water under basic reaction conditions; can usually not be cleared by renal filtration, and thus have prolonged half-lives in plasma
11/06/2008US20080274068 External Preparation for Skin Containing a Phosphorlated Saccharide
11/06/2008US20080274064 Utilization of rhinologically active substances
11/06/2008US20080274061 Method for Treating a Restless Limb Disorder
11/06/2008US20080274060 Therapeutic Foam
11/06/2008US20080274058 substrates for amyloidogenic proteins, for example, A beta 1-42, an amyloid protein, brain deposits of which are associated with Alzheimer's disease
11/06/2008US20080274045 Imaging, diagnosis and treatment of disease
11/06/2008US20080274044 aqueous dispersion comprising insoluble therapeutic or diagnostic agent particles having a surface modifier; treating a respiratory illness
11/06/2008DE102007023397A1 Neue pharmazeutische Zusammensetzung zur Verwendung als Laxativum Novel pharmaceutical composition for use as a laxative
11/06/2008DE102007021149A1 Preparing prenylated aromatic compounds, useful in pharmacy and as antibiotic, comprises incubating an aromatic substrate and a prenylating substance with prenyltransferase
11/06/2008DE102007020799A1 Transdermales therapeutisches System mit Remifentanil Transdermal therapeutic system with remifentanil
11/06/2008DE102007020690A1 Neue amorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-mehtyl-1-butoxy)-6[4-methylsulfonyl)phenyl]-3(2H)-pyridazinon (FHMP) New amorphous form of 2- (4-fluorophenyl) -4-3-hydroxy-3-mehtyl-1-butoxy) -6 [4-methylsulfonyl) phenyl] -3 (2H) -pyridazinone (FHMP)
11/06/2008DE102007020689A1 Neue polymorphe Form von 2-(4-Fluorophenyl)-4-3-hydroxy-3-methyl-1-butoxy-5-[4-methylsulfonyl)phenyl]3/2H)-pyridazinon (FHMP) Novel polymorph of 2- (4-fluorophenyl) -4-3-hydroxy-3-methyl-1-butoxy-5- [4-methylsulfonyl) phenyl] 3 / 2H) -pyridazinone (FHMP)
11/06/2008DE102007020493A1 Substituierte Amid-Derivate Substituted amide derivatives
11/06/2008DE102007020492A1 Substituierte Sulfonamid-Derivate Substituted sulfonamide derivatives
11/06/2008CA2756791A1 Trpv1 antagonists and uses thereof
11/06/2008CA2689982A1 Compositions and approaches for increasing diet induced thermogenesis, inducing weight loss and maintaining muscle mass and strength
11/06/2008CA2688662A1 Methods for synthesizing and purifying aminoalkyl tetracycline compounds
11/06/2008CA2688514A1 Rna interference suppression of neurodegenerative diseases and methods of use thereof
11/06/2008CA2688233A1 Erythropoietin complementation or replacement
11/06/2008CA2687943A1 N'-(phenyl)-n-(morpholin-4-yl-pyridin-2-yl)-pyrimidine-2,4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions
11/06/2008CA2686125A1 Pseudopterosin-producing bacteria and methods of use
11/06/2008CA2685739A1 Hydroxy sulfonate of quinone compounds and their uses
11/06/2008CA2685591A1 Pharmaceutical nimodipine compositions
11/06/2008CA2685534A1 Use of matrix metalloproteinase inhibitors in skin care
11/06/2008CA2685529A1 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
11/06/2008CA2685524A1 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
11/06/2008CA2685522A1 High viscosity macromolecular compositions for treating ocular conditions
11/06/2008CA2685507A1 Substituted sulfonamide derivatives
11/06/2008CA2685503A1 Substituted amide derivatives
11/06/2008CA2685473A1 Treatment of virally induced lesions
11/06/2008CA2685444A1 Rna antagonist compounds for the modulation of beta-catenin
11/06/2008CA2685362A1 Compositions and methods for transmucosal delivery of domperidone
11/06/2008CA2685344A1 Deuterium labelled ketamine
11/06/2008CA2685341A1 Macrophage transfection method
11/06/2008CA2685332A1 Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
11/06/2008CA2685331A1 Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
11/06/2008CA2685268A1 Compositions of tolperisone
11/06/2008CA2685266A1 Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
11/06/2008CA2685264A1 Compounds and methods for enhancing solubility of florfenicol and structurally-related antibiotics using cyclodextrins
11/06/2008CA2685247A1 New 4,8-diphenyl-polyazanaphthalene derivatives
11/06/2008CA2685184A1 Solid dosage forms
11/06/2008CA2685134A1 Use of cyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia
11/06/2008CA2685131A1 Stable solid preparation containing 4,5-epoxymorphinan derivative
11/06/2008CA2685128A1 Use of acyclically substituted furopyrimidine derivatives for treating pulmonary arterial hypertonia
11/06/2008CA2685126A1 Therapeutic or prophylactic agent for dyskinesia
11/06/2008CA2685121A1 Therapeutic agents useful for treating pain
1 ... 3009 3010 3011 3012 3013 3014 3015 3016 3017 3018 3019 3020 3021 3022 3023 3024 3025 3026 3027 3028 3029 ... 7860